C' ELLS of transplanted experimental t tiniours, whein injected into genetically compatible hosts in admixture with Bacillus Calmette Gue'rin (BCG) organisms, often fail to produce progressively growing tinmouirs (Laucius et al., 1974) . Host responses are involved in this adjuvant contact therapy, since BCG vaccines are not directly cytotoxic for tumour cells and systemic host immunity may follow rejection of mixed BCG + cell inocula, buit the precise nature of these responses is unclear. Tests with transplanted mouse sarcomata (Bartlett, Zbar and Rapp, 1972; Chung, Zbar and Rapp, 1973) demonstrated that immunosuppression by thymectomy and whole body irradiation, or treatment with antithymocyte serum, abrogated the local suppressive activity of BCG. In marked contrast, Moore, Lawrence and Nisbet (1975) have demonstrated that immunosuppression by thymectomy and irradiation does not abrogate the contact suppressive action of BCG( for sarcomata in the rat. In addlition, rat tumour xenografts in congenitallA-athymic (nude) mice are suppressed when cells are transplanted in admixture with BCG organisms (Pimm and Baldwin, 1975) Influence of whole body irradiation on local tumour-suppressive action of BCG.- Table I shows the tumour-suppressive action of BCG where injected s.c. in admixture with cells of sarcoma Mc7 prepared from solid tissue or harvested from in vitro culture into normal rats and animals exposed to 450 rad y-irradiation. In all tests, with both normal and irradiated animals, admixture with BCG prevented tumour development in almost all rats, tumour cells alone, whether from solid in vivo growths or in vitro culture, growing out in the majority of normal or irradiated animals.
Inltuence of whole body irradiation on induction of tumour immunity by mixed tumour cell + BCG inocula.-It has previously been established that injection of a mixed inoculum of sarcoma Mc7 cells and BCG elicits tumour-specific immunity against further challenge with cells of the same tumour (Baldwin and Pimm, 1973) . Moreover, treatment of rats with normal animals rejecting mixed inocula of tumour cells + BCG rejected a contralateral challenge of 106 tissue-culturederived cells, but this therapeutic response was abrogated in 5/6 pre-irradiated rats.
These studies demonstrate that whole body irradiation (450 rad) 24 h beforehand does not abrogate the local suppressive effect of BCG injected in admixture with sarcoma Mc7 cells. In contrast, the development of tumourspecific host immunity, normally occurring concomitantly with rejection of mixed inocula, was totally abrogated by whole body irradiation. The possibility that local contact suppression mediated by BCG was due to lymphoid cells present in tumour cell suspensions is excluded by the identical results achieved with tissueculture-derived cells.
These findings are in contrast to those of Bartlett et al. (1972) and Chung et al. (1973) where full host immunocompetence, or at least prior immunization to BCG, was necessary for local suppression of mouse sarcomata. However, Moore et al. (1975) , in a series of experiments with transplanted sarcomata in the rat, have shown that immunosuppression by sublethal whole body irradiation, with or without prior thymectomy, did not abrogate the local suppressive action of BCG. In the present studies, the level of immunosuppression produced by simple whole body irradiation has not been characterized, but it has been clearly demonstrated that irradiated animals, while rejecting mixed inocula of cells + BCG, fail to develop the systemic tumour immunity normally capable of controlling a simultaneous challenge with tumour cells alone. The present findings and those of Moore et al. (1975) demonstrate, therefore, that fundamentally different host responses are involved in these two events and that full host immunocompetence is not necessary for BCG contact therapy. This is further supported by the previous demonstration of BCG contact suppression of rat tumour xenografts in athymic nude mice (Pimm and Baldwin, 1975) .
Although the evidence presented here suggests that augmented systemic responses to tumour-associated rejection antigens are not essential for BCG contact suppression, the nature of the responses involved have yet to be elucidated. It has been demonstrated, however, that with rat tumours, both in syngeneic hosts and athymic mice, the local suppressive action of BCG can be abrogated by silica treatment of the host (Hopper, Pimm and Baldwin, 1976) . Silica is known to be selectively toxic for macrophages and the probability that local BCG activation of host macrophages is the primary tumour-suppressive event in adjuvant contact therapy with this agent is under investigation. This work was supported by the Cancer Research Campaign. BCG vaccine was supplied by Glaxo Research Ltd. We thank Mrs A. P. WVilcox for skilful technical assistance.
